Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis

We examined whether eldecalcitol (ELD) provided additive bone mineral density (BMD) and bone turnover marker gains in patients undergoing long-term bisphosphonate (BP) usage, especially in osteoporotic individuals exhibiting a poor response to BPs